ArticleParkinsonism & related disorders2025
Parkinson's disease mild cognitive impairment with MRI evidence of cholinergic nucleus 4 degeneration: A new subtype?
Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic Associations of Parkinson's Disease Clinical, Pathological, and Data-Driven Subtypes.Genes · 2026Article
- Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker.Frontiers in aging neuroscience · 2026Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
backgroundSubtyping Parkinson's disease with mild cognitive impairment (PD-MCI) into clinically and pathologically homogeneous groups could improve clinical trials and enable personalized treatments. Cholinergic nucleus 4 (Ch4) degeneration has been linked to cognitive decline in PD, suggesting a distinct PD-MCI subtype with worse prognosis.
objectiveTo determine whether PD-MCI patients with MRI evidence of Ch4 degeneration exhibit a different clinical profile and cognitive trajectory than those without Ch4 degeneration.
methodsWe analyzed baseline MRI scans from 162 PD-MCI participants in the Parkinson's Progression Markers Initiative. Ch4 grey matter density (GMD) was assessed using voxel-based morphometry and probabilistic maps. Participants were classified as having low or normal Ch4 GMD using a z-score threshold of 1 SD below the mean. We compared clinical features and time to cognitive milestones using Kaplan-Meier survival analysis.
resultsOf 162 participants, 40 had low Ch4 GMD and 122 had normal Ch4 GMD. Those with low Ch4 GMD had significantly worse MDS-UPDRS total and subscale scores (II-III), greater autonomic dysfunction, and reduced olfaction (all P < 0.05). PD-MCI patients with low Ch4 GMD progressed faster to cognitive decline milestones (log-rank P = 0.0017). Subtyping PD-MCI patients by Ch4 GMD may provide more prognostic accuracy for capturing earlier cognitive progression compared to currently established PD subtypes.
conclusionPD-MCI patients with Ch4 degeneration may represent a distinct, clinically severe PD-MCI subtype with faster progression. This group may benefit from targeted inclusion in clinical trials, particularly those assessing cholinergic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.